Mark Wade

Dr. Mark Wade

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2014 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MWMark Wade
Mark Wade
DJDominic Jones
Dominic Jones
LWLaura Wilson
Laura Wilson
JSJacqueline Stockley
Jacqueline Stockley
KCKelly Coffey
Kelly Coffey
LGLuke Gaughan
Luke Gaughan
Endocrine therapy has successfully been used to treat estrogen receptor (ER)-positive breast cancer, but this invariably fails with cancers becoming refractory to treatment. Emerging evidence has suggested that fluctuations in ER co-regulatory protein expression may facilitate resistance to therapy and be involved in breast cancer progression. To date, a small number of enzymes that control methylation status of histones have been identified as co-regulators of ER signalling. We have identified the histone H3 lysine 9 mono- and di-methyl demethylase enzyme KDM3A as a positive regulator of ER activity. Here, we demonstrate that depletion of KDM3A by RNAi abrogates the recruitment of the ER to cis-regulatory elements within target gene promoters, thereby inhibiting estrogen-induced gene expression changes. Global gene expression analysis of KDM3A-depleted cells identified gene clusters associated with cell growth. Consistent with this, we show that knockdown of KDM3A reduces ER-positive cell proliferation and demonstrate that KDM3A is required for growth in a model of endocrine therapy-resistant disease. Crucially, we show that KDM3A catalytic activity is required for both ER-target gene expression and cell growth, demonstrating that developing compounds which target demethylase enzymatic activity may be efficacious in treating both ER-positive and endocrine therapy-resistant disease.

30 May 2013 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
LGLuke Gaughan
Luke Gaughan
JSJacqueline Stockley
Jacqueline Stockley
KCKelly Coffey
Kelly Coffey
DODaniel O’neill
Daniel O’neill
DJDominic L. Jones
Dominic L. Jones
CRCraig N. Robson
Craig N. Robson
The importance of the estrogen receptor (ER) in breast cancer (BCa) development makes it a prominent target for therapy. Current treatments, however, have limited effectiveness, and hence the definition of new therapeutic targets is vital. The ER is a member of the nuclear hormone receptor superfamily of transcription factors that requires co-regulator proteins for complete regulation. Emerging evidence has implicated a small number of histone methyltransferase (HMT) and histone demethylase (HDM) enzymes as regulators of ER signalling, including the histone H3 lysine 9 tri-/di-methyl HDM enzyme KDM4B. Two recent independent reports have demonstrated that KDM4B is required for ER-mediated transcription and depletion of the enzyme attenuates BCa growth in vitro and in vivo. Here we show that KDM4B has an overarching regulatory role in the ER signalling cascade by controlling expression of the ER and FOXA1 genes, two critical components for maintenance of the estrogen-dependent phenotype. KDM4B interacts with the transcription factor GATA-3 in BCa cell lines and directly co-activates GATA-3 activity in reporter-based experiments. Moreover, we reveal that KDM4B recruitment and demethylation of repressive H3K9me3 marks within upstream regulatory regions of the ER gene permits binding of GATA-3 to drive receptor expression. Ultimately, our findings confirm the importance of KDM4B within the ER signalling cascade and as a potential therapeutic target for BCa treatment.

15 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
FMFiona K. Middleton
Fiona K. Middleton
MPMiranda J. Patterson
Miranda J. Patterson
CEClaire J. Elstob
Claire J. Elstob
SFSarah Fordham
Sarah Fordham
AHAshleigh Herriott
Ashleigh Herriott
NCNicola Curtin
Nicola Curtin
Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition

13 August 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
DJDominic Jones
Dominic Jones
MWMark Wade
Mark Wade
SNSirintra Nakjang
Sirintra Nakjang
LCLewis Chaytor
Lewis Chaytor
JGJames Grey
James Grey
LGLuke Gaughan
Luke Gaughan
FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer

22 December 2014 in Oncogene
Verified
Journal Article
Open access
PDF file
MWMark Wade
Mark Wade
NSN J Sunter
N J Sunter
SFS E Fordham
S E Fordham
ALA Long
A Long
DMD Masic
D Masic
JAJ M Allan
J M Allan
Ionising radiation is a potent human carcinogen. Epidemiological studies have shown that adolescent and young women are at increased risk of developing breast cancer following exposure to ionising radiation compared with older women, and that risk is dose-dependent. Although it is well understood which individuals are at risk of radiation-induced breast carcinogenesis, the molecular genetic mechanisms that underlie cell transformation are less clear. To identify genetic alterations potentially responsible for driving radiogenic breast transformation, we exposed the human breast epithelial cell line MCF-10A to fractionated doses of X-rays and examined the copy number and cytogenetic alterations. We identified numerous alterations of c-MYC that included high-level focal amplification associated with increased protein expression. c-MYC amplification was also observed in primary human mammary epithelial cells following exposure to radiation. We also demonstrate that the frequency and magnitude of c-MYC amplification and c-MYC protein expression is significantly higher in breast cancer with antecedent radiation exposure compared with breast cancer without a radiation aetiology. Our data also demonstrate extensive intratumor heterogeneity with respect to c-MYC copy number in radiogenic breast cancer, suggesting continuous evolution at this locus during disease development and progression. Taken together, these data identify c-MYC as a radiosensitive locus, implicating this oncogenic transcription factor in the aetiology of radiogenic breast cancer.

6 August 2019 in Cancers
Verified
Journal Article
Open access
PDF file
DJDominic Jones
Dominic Jones
LWLaura Wilson
Laura Wilson
HTHuw Thomas
Huw Thomas
LGLuke Gaughan
Luke Gaughan
MWMark Wade
Mark Wade
Many estrogen receptor (ER)-positive breast cancers develop resistance to endocrine therapy but retain canonical receptor signalling in the presence of selective ER antagonists. Numerous co-regulatory proteins, including enzymes that modulate the chromatin environment, control the transcriptional activity of the ER. Targeting ER co-regulators has therefore been proposed as a novel therapeutic approach. By assessing DNA-binding dynamics in ER-positive breast cancer cells, we have identified that the histone H3 lysine 9 demethylase enzymes, KDM3A and KDM4B, co-operate to regulate ER activity via an auto-regulatory loop that facilitates the recruitment of each co-activating enzyme to chromatin. We also provide evidence that suggests that KDM3A primes chromatin for deposition of the ER pioneer factor FOXA1 and recruitment of the ER-transcriptional complex, all prior to ER recruitment, therefore establishing an important mechanism of chromatin regulation involving histone demethylases and pioneer factors, which controls ER functionality. Importantly, we show via global gene-expression analysis that a KDM3A/KDM4B/FOXA1 co-regulated gene signature is enriched for pro-proliferative and ER-target gene sets, suggesting that abrogation of this network could be an efficacious therapeutic strategy. Finally, we show that depletion of both KDM3A and KDM4B has a greater inhibitory effect on ER activity and cell growth than knockdown of each individual enzyme, suggesting that targeting both enzymes represents a potentially efficacious therapeutic option for ER-driven breast cancer.